DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 Agosto 2023 - 7:05AM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics technology, today announced the grant to six new employees
of restricted stock units representing the contingent right to
receive up to an aggregate of 24,720 shares of the Company’s common
stock under its 2022 Inducement Equity Incentive Plan, as amended,
or the 2022 Inducement Plan. The restricted stock units were
approved by DermTech’s Compensation Committee, effective August 22,
2023, and were granted as inducements material to the employee’s
acceptance of employment with DermTech in accordance with Nasdaq
Listing Rule 5635(c)(4).
The 24,720 restricted stock units shall vest over 4 years as
follows: (i) twenty-five percent of the restricted stock units will
vest on September 5, 2024 and (ii) the remaining seventy-five
percent of the restricted stock units will vest in equal quarterly
installments until fully vested on September 5, 2027, subject to
the employee’s continued employment with the Company on these
vesting dates. The restricted stock units are also subject to the
terms and conditions of the 2022 Inducement Plan, and the terms and
conditions of the equity award agreements covering the grants.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics technology. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believe,” “predict,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential growth, financial outlook and future financial
performance, ability to increase its proportion of reimbursed
billable samples, ability to maintain or improve its operating
efficiency and reduce operating expenses, the sufficiency of
DermTech’s cash resources and runway and ability to access capital
to fund its operating plan, the sufficiency of its cash resources
to fund planned operations for the anticipated period, anticipated
annual cash savings to be realized from the restructuring,
implications and interpretations of any study results, and
expectations regarding agreements with or reimbursement or cash
collection patterns from government payers (including Medicare) or
commercial payers and related billing practices or number of
covered lives. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from the expected results. Most of these factors
are outside of the control of DermTech and are difficult to
predict. Factors that may cause such differences include, but are
not limited to: (1) the outcome of any legal proceedings that may
be instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
government payers (including Medicare) and commercial payers; (5)
the ability of patients or healthcare providers to obtain coverage
of or sufficient reimbursement for DermTech’s products; (6)
DermTech’s ability to grow, manage growth and retain its key
employees and maintain or improve its operating efficiency and
reduce operating expenses; (7) changes in applicable laws or
regulations; (8) the market adoption and demand for DermTech’s
products and services together with the possibility that DermTech
may be adversely affected by other economic, business, and/or
competitive factors; and (9) other risks and uncertainties included
in the “Risk Factors” section of the most recent Annual Report on
Form 10-K filed by DermTech with the Securities and Exchange
Commission (the “SEC”), and other documents filed or to be filed by
DermTech with the SEC, including subsequently filed reports.
DermTech cautions that the foregoing list of factors is not
exclusive. You should not place undue reliance upon any forward-
looking statements, which speak only as of the date made. DermTech
does not undertake or accept any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement
is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230825747268/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
DermTech (NASDAQ:DMTK)
Gráfica de Acción Histórica
De May 2023 a May 2024